Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 3Meningeal Carcinomatosis 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Neurofibromatosis 1 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Astrocytoma 1

Interventions

Everolimus 2lorlatinib 1liposomal doxorubicin 1encorafenib 1binimetinib 1Taxes 1Radiotherapy 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Cetuximab 1Carboplatin 1Albumin-Bound Paclitaxel 1AZD1390 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × lorlatinib × CNS × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡